Dendritic cells infected with a vaccinia virus interleukin-2 vector secrete high levels of IL-2 and can become efficient antigen presenting cells that secrete high levels of the immunostimulatory cytokine IL-12

Cancer Gene Therapy

Volumn 10, Issue 8, 2003, Pages 591-602

  Mukherjee, Sutapa ^a   Upham, John W ^a   Ramshaw, Ian ^b   Bundell, Christine ^a   Van Bruggen, Ivonne ^a   Robinson, Bruce W S ^a,c   Nelson, Delia J ^a,c,d  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Biology and Environment   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d CURTIN UNIVERSITY   (Australia)

Author keywords

Cytokine gene transfer; Dendritic cells; IL 2; Vaccinia virus vector

Indexed keywords

B7 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; LIPOPOLYSACCHARIDE; MEMBRANE ANTIGEN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CELL LYSATE; CELL MATURATION; CYTOKINE RELEASE; DENDRITIC CELL; DONOR; GENE EXPRESSION SYSTEM; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IMMUNOSTIMULATION; MAMMAL CELL; MONOCYTE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY; VACCINIA VIRUS; VIROGENESIS; VIRUS INFECTION; VIRUS RECOMBINANT;

ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CELL LINE, TUMOR; DENDRITIC CELLS; DOWN-REGULATION; GENE THERAPY; GENETIC VECTORS; HUMANS; INTERLEUKIN-12; INTERLEUKIN-2; MONOCYTES; T-LYMPHOCYTES; TRANSFECTION; UP-REGULATION; VACCINIA VIRUS;

MAMMALIA; VACCINIA VIRUS;

EID: 0042232462     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700604     Document Type: Article

References (51)

1. Finke J, Ferrone S, Frey A, et al. Where have all the T-cells gone? Mechanisms of immune evasion by tumors. Immunol Today. 1999;20:158-160.
2. Marzo AL, Lake RA, Lo D, et al. Tumor antigens are constitutively presented in the draining lymph nodes. J Immunol. 1999;162:5838-5845.
3. Nelson DJ, Mukherjee S, Bundell C, et al. Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL. J Immunol. 2001;166:5557-5566.
4. Mukherjee S, Haenel T, Himbeck R, et al. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Ther. 2000;7:663-670.
5. Bernsen MR, Tang JW, Everse LA, et al. Interleukin 2 (IL-2) therapy: potential advantages of locoregional versus systemic administration. Cancer Treat Rev. 1999;25:73-82.
6. Pantuck AJ, Belldegrun AS. Phase I clinical trial of interleukin 2 (IL-2) gene therapy for prostate cancer. Curr Urol Rep. 2001;2:33.
7. Tartour E, Mehtali M, Sastre-Garau X, et al. Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings. Br J Cancer. 2000;83:1454-1461.
8. Dorval T, Mathiot C, Chosidow O, et al. IL-2 phase II trial in metastatic melanoma: analysis of clinical and immunological parameters. Biotechnol Ther. 1992;3:63-79.
9. Castagneto B, Zai S, Mutti L, et al. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: results of a phase II study on 31 consecutive patients. Lung Cancer. 2001;31:303-310.
10. Krastev Z, Koltchakov V, Vladov N, et al. A mesothelioma that is sensitive to locally applied IL-2. Cancer Immunol Immunother. 2001;50:226-227.
11. Steinman RM, Inaba K, Turley S, et al. Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies. Hum Immunol. 1999;60:562-567.
12. Huang AY, Golumbek P, Ahmadzadeh M, et al. Role of bone marrow-derived cells in presenting MHC class 1-restricted tumor antigens. Science. 1994;264:961-965.
13. Bennett SR, Carbone FR, Karamalis F, et al. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T-cell help. J Exp Med. 1997;186:65-70.
14. Marzo AL, Lake RA, Robinson BWS, et al. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res. 1999;59:1071-1079.
15. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer. 2001;94:459-473.
16. Nouri-Shirazi M, Banchereau J, Fay J, et al. Dendritic cell based tumor vaccines. Immunol Lett. 2000;74:5-10.
17. Celluzzi CM, Mayordomo JI, Storkus WJ, et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med. 1996;183:283-287.
18. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-332.
19. Zhou Y, Bosch ML, Salgaller ML. Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J Immunother. 2002;25:289-303.
20. Tirapu I, Rodriguez-Calvillo M, Qian C, et al. Cytokine gene transfer into dendritic cells for cancer treatment. Curr Gene Ther. 2002;2:79-89.
21. Berard F, Blanco P, Davoust J, et al. Cross-priming of naive CD8 T-cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med. 2000;192:1535-1544.
22. Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T-cell function in humans after injection of immature dendritic cells. J Exp Med. 2001;193:233-238.
23. Drillien R, Spehner D, Bohbot A, et al. Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes. Virology 2000;268:471-481.
24. Jenne L, Hauser C, Arrighi JF, et al. Poxvirus as a vector to transduce human dendritic cells for immunotherapy: abortive infection but reduced APC function. Gene Therapy. 2000;7:1575-1583.
25. Engelmayer J, Larsson M, Subklewe M, et al. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J Immunol. 1999;163:6762-6768.
26. Drexler I, Antunes E, Schmitz M, et al. Modified vaccinia virus ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen a*0201-restricted cytotoxic T-cells in vitro and in vivo. Cancer Res. 1999;59:4955-4963.
27. Kim CJ, Cormier J, Roden M, et al. Use of recombinant poxviruses to stimulate anti-melanoma T-cell reactivity. Ann Surg Oncol. 1998;5:64-76.
28. Yang S, Kittlesen D, Slingluff Jr. CL, et al. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-α2 and -α3. J Immunol. 2000;164:4204-4211.
29. Kedl RM, Rees WA, Hildeman DA, et al. T-cells compete for access to antigen-bearing antigen -presenting cells. J Exp Med. 2000;192:1105-1113.
30. Norbury CC, Malide D, Gibbs JS, et al. Visualizing priming of virus-specific CD8 + T-cells by infected dendritic cells in vivo. Nat Immunol. 2002;3:265.
31. Nossal GJ. Tolerance and ways to break it. Ann NY Acad Sci. 1993;690:34-41.
32. Tham EL, Shrikant P, Mescher MF. Activation-induced nonresponsiveness: a Th-dependent regulatory checkpoint in the CTL response. J Immunol. 2002;168:1190-1197.
33. Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med. 1994;180:83-93.
34. Ramshaw IA, Andrew ME, Phillips SM, et al. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature. 1987;329:545-546.
35. Warren HS, Kinnear BF, Skipsey LJ. Human natural killer (NK) cells: requirements for cell proliferation and expansion of phenotypically novel subpopulations. Immunol Cell Biol. 1993;71:87-97.
36. Brossart P, Goldrath AW, Butz EA, et al. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol. 1997;158:3270-3276.
37. Di Nicola M, Siena S, Bregni M, et al. Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors. Cancer Gene Ther. 1998;5:350-356.
38. Kim CJ, Prevette T, Cormier J, et al. Dendritic cells infected with poxviruses encoding MART-1/melan A sensitize T lymphocytes in vitro. J Immunother. 1997;20:276-286.
39. Bronte V, Carroll MW, Goletz TJ, et al. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci USA. 1997;94:3183-3188.
40. Akiyama Y, Watanabe M, Maruyama K, et al. Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines. Gene Therapy. 2000;7:2113-2121.
41. Shimizu K, Fields RC, Giedlin M, et al. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc Natl Acad Sci USA. 1999;96:2268-2273.
42. Shimizu K, Fields RC, Redman BG, et al. Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2. Cancer J Sci Am. 2000;6(Suppl 1):S67-S75.
43. Eggert AO, Becker JC, Ammon M, et al. Specific peptide-mediated immunity against established melanoma tumors with dendritic cells requires IL-2 and fetal calf serum-free cell culture. Eur J Immunol. 2002;32:122-127.
44. Faulkner L, Buchan G, Lockhart E, et al. IL-2 linked to a peptide from influenza hemagglutinin enhances T-cell activation by affecting the antigen-presentation function of bone marrow-derived dendritic cells. Int Immunol. 2001;13:713-721.
45. Granucci F, Vizzardelli C, Pavelka N, et al. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat Immunol. 2001;2:882-888.
46. Sauter B, Albert ML, Francisco L, et al. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med. 2000;191:423-434.
47. Ferlazzo G, Semino C, Spaggiari GM, et al. Dendritic cells efficiently cross-prime HLA class I-restricted cytolytic T lymphocytes when pulsed with both apoptotic and necrotic cells but not with soluble cell-derived lysates. Int Immunol. 2000;12:1741-1747.
48. Kotera Y, Shimizu K, Mule JJ. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res. 2001;61:8105-8109.
49. Fernando GJP, Stewart TJ, Tindle RW, et al. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model. J Immunol. 1998;161:2421-2427.
50. Nishimura T, Iwakabe K, Sekimoto M, et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med. 1999;190:617-627.
51. Kuniyoshi JS, Kuniyoshi CJ, Lim AM, et al. Dendritic cell secretion of IL-15 is induced by recombinant huCD40Lt and augments the stimulation of antigen-specific cytolytic T-cells. Cell Immunol. 1999;193:48-58.